Figures computed from official regulatory filings — .
Ownershipinsiders 6.75% · institutions 39.32%
In EUR · as of Oct 19, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for GENSIGHT BIOLOGICS S.A. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
GenSight Biologics S.A., a clinical-stage biotechnology company, discovers, develops, and commercializes novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its lead product candidates include LUMEVOQ, a recombinant AAV2-based gene therapy, which is in Phase III clinical trials for the treatment of leber hereditary optic neuropathy caused by a mutated ND4 gene; and GS030, which is in Phase I/II clinical trial for the treatment of retinitis pigmentosa and dry age-related macular degeneration. The company is also developing products that are in preclinical stage targeting ophthalmic and neurodegenerative diseases. It has license agreements with Sorbonne Université, CNRS, Inserm and SATT Lutech; Inserm Transfert S.A, Genethon, and Harvard; Massachusetts Institute of Technology; Novartis Pharma AG; Sorbonne University, Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale and Satt Lutech; Association Française contre les Myopathies, Inserm Transfert S.A; and non-exclusive license agreement with Adverum Biotechnologies. The company was incorporated in 2012 and is headquartered in Paris, France.
Market information source · Oct 19, 2026
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| Sofinnova Partners SAStrack record | Award | $1.2M | AMF |
| Sofinnova Partners SAStrack record | Award | $217K | AMF |
| Sofinnova Partners SAStrack record | Award | $780.5K | AMF |
| Sofinnova Partners SAStrack record | Award | $1.1M | AMF |
| Sofinnova Partners SAStrack record | Award | $2.2M | AMF |
| Sofinnova Partners SAStrack record | Award | $2.2M | AMF |
| Sofinnova Partners SAStrack record | Award | $1.5M | AMF |
| Sofinnova Partners SAStrack record | Other | $2.4M | AMF |
| Sofinnova Partners SAStrack record | Award | $2.3M | AMF |
| Bernard Gilly | Buy | $127.2K | conv 73First in 12mo | AMF |
| Sofinnova Partners SAStrack record | Award | $4.4M | AMF |
| Sofinnova Partners SAStrack record | Award | $5.3M | AMF |
| Sofinnova Partners SAStrack record | Award | $3.5M | AMF |
| Sofinnova Partners SAStrack record | Award | $9.8M | AMF |